Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
株式のランク
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
株価
$4.87
時価総額
$4.36B
変化（1日）
-5.47%
変化（1年）
-15.62%
国
CN
取引 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
カテゴリー
Healthcare
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd（688336）のEPS
2026 時点のEPS TTM: 0
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltdの最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Sunshine Guojian Pharmaceutical (Shanghai) Co., LtdのEPS履歴（2006から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2025 | $0.67 | 330.09% |
| 2024 | $0.16 | 130.38% |
| 2023 | $0.07 | 484.48% |
| 2022 | $0.01 | 146.81% |
| 2021 | 0.00 | -108.30% |
| 2020 | $-0.06 | -191.59% |
| 2019 | $0.06 | -40.97% |
| 2018 | $0.10 | -10.36% |
| 2017 | $0.12 | 53.08% |
| 2016 | $0.08 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | $0.08 | 34.33% |
| 2011 | $0.06 | 20.60% |
| 2010 | $0.05 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $13.70 | - |
BE
|
|
| $27.74 | - |
NL
|
